Previous close | 2.6000 |
Open | N/A |
Bid | 0.9500 |
Ask | 3.6000 |
Strike | 5.00 |
Expiry date | 2024-08-16 |
Day's range | 2.6000 - 2.6000 |
Contract range | N/A |
Volume | |
Open interest | 2 |
Generally, when a single insider buys stock, it is usually not a big deal. However, when several insiders are buying...
92% (12/13) overall response rate (ORR) for relapsed/refractory AL Amyloidosis patients enrolled in NEXICART-1: 12 out of 12 patients not exposed to prior BCMA-targeted bispecific responded to NXC-201 (100% ORR), of which 9 out of 12 were complete responders (75% CRs) 1 patient with prior exposure to BCMA-targeted bispecific treatment did not respond Best responder duration of response was 28.0 months with response ongoing as of May 10, 2024U.S. prevalence of relapsed/refractory AL Amyloidosis i
European Orphan Drug Designation (“ODD”) qualifies NXC-201 for: 10 years of market exclusivity once authorized in the EUAccess to the EU centralized authorization procedureReduced fees for: EU protocol assistance, marketing authorization applications, inspections before authorization, applications for changes to marketing authorizations made after approval, and reduced annual fees LOS ANGELES, April 29, 2024 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“Immix Biopharma”, “Company”, “We” or “Us”, N